Congressional Committee Orders Federal Review of State Marijuana Laws and Diversion Risks

A pivotal move in federal cannabis oversight emerged this week as the House Appropriations Committee approved a directive requiring federal agencies to assess the effectiveness of state-level marijuana regulations. This mandate, attached to the Fiscal Year 2027 Financial Services and General Government (FSGG) spending bill, calls for a coordinated review by the Treasury Department’s Alcohol and Tobacco Tax and Trade Bureau (TTB) and other agencies. The committee specifically seeks an evaluation of both the commonalities and unique enforcement strategies among the more than 20 states and territories permitting adult-use cannabis, as well as the over 35 that allow medical use

The committee’s report goes beyond a simple regulatory review, urging agencies to recommend improvements for data sharing and coordination between state and federal authorities. Notably, it also instructs the Department of Justice (DOJ), in concert with TTB and other regulatory bodies, to identify effective methods for preventing the diversion of legally produced cannabis into states where marijuana remains prohibited. According to the directive, "The Committee urges DOJ, in coordination with the broader Department, TTB, and other agencies that may have relevant regulatory expertise, to coordinate an assessment of the most effective methods of preventing diversion of state legal cannabis product into jurisdictions that do not permit the use of cannabis."

This push for federal evaluation mirrors similar provisions included in previous appropriations cycles, though there is little evidence that TTB has ever submitted a comprehensive cannabis policy report to Congress. The directive aligns with legislative efforts by House FSGG Appropriations Subcommittee Chairman Dave Joyce (R-OH), who has introduced standalone bills aiming to lay the groundwork for federal cannabis legalization. These efforts seek to establish a commission to develop recommendations for a federal regulatory framework, signaling a growing interest in harmonizing state and federal cannabis policies

While the House Appropriations Committee seeks to advance cannabis policy studies, the underlying FSGG bill continues to block Washington, D.C. from legalizing and regulating recreational marijuana sales. This longstanding provision, championed by Rep. Andy Harris (R-MD), restricts the District from using local funds to enact or implement laws reducing penalties for Schedule I substances, including cannabis. D.C. Delegate Eleanor Holmes Norton strongly criticized the bill’s anti-home-rule riders, stating, “These members were not elected by D.C. residents, yet they continue to treat the District like their own playground to rule as they please.”

On Capitol Hill, momentum for broader cannabis reform appears strong among Democrats and some Republicans. House Minority Leader Hakeem Jeffries (D-NY) remarked, “This does seem to exist as a bipartisan issue, particularly amongst younger generations of Republicans and the entirety of the House Democratic Caucus, and we know that the votes do exist to act legislatively.” Meanwhile, the Department of Justice has announced progress toward federal marijuana rescheduling, and bipartisan efforts are underway to address upcoming federal restrictions on hemp-derived THC products

From the OG Lab newsroom perspective, this directive represents another step toward reconciling the patchwork of state cannabis laws with evolving federal attitudes. The call for comprehensive assessments and diversion prevention strategies signals that Congress is seeking a more unified approach to cannabis oversight. Industry stakeholders should pay close attention to the outcomes of these federal studies and the ongoing debate over D.C.'s autonomy, as both could significantly influence the future regulatory landscape for cannabis in the United States